Original Article

You have full text access to this OnlineOpen article

Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs

  1. Matthew R Allen1,*,
  2. Daniel J Kubek1,
  3. David B Burr1,2,3

Article first published online: 18 DEC 2009

DOI: 10.1359/jbmr.090713

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 98–105, January 2010

Additional Information

How to Cite

Allen, M. R., Kubek, D. J. and Burr, D. B. (2010), Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res, 25: 98–105. doi: 10.1359/jbmr.090713

Author Information

  1. 1

    Department of Anatomy and Cell Biology, Indianapolis, IN, USA

  2. 2

    Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN, USA

  3. 3

    Department of Biomedical Engineering Program, Indiana University–Purdue University Indianapolis, Indianapolis, IN, USA

*Department of Anatomy and Cell Biology, 635 Barnhill Drive, MS-5035, Indianapolis, IN 46202, USA.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 18 DEC 2009
  3. Manuscript Accepted: 1 JUL 2009
  4. Manuscript Revised: 28 APR 2009
  5. Manuscript Received: 27 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (173K)

References

  • 1
    Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007; 86: 1022–1033.
  • 2
    Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007; 257: 16–35.
  • 3
    Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006; 6: 307–312.
  • 4
    Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97: 2692–2696.
  • 5
    Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479–1491.
    Direct Link:
  • 6
    Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144: 753–761.
  • 7
    Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006; 81: 1047–1053.
  • 8
    Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA. 2006; 295: 2833–2836.
  • 9
    Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65: 415–423.
  • 10
    American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006; 137: 1144–1150.
  • 11
    Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104: 83–93.
    Direct Link:
  • 12
    Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 1567–1575.
  • 13
    Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102: 433–441.
  • 14
    Allen MR. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs. 2009; 189: 289–294.
  • 15
    Garetto LP, Tricker ND. Remodeling of bone surrounding the implant interface. In: GarettoLP, TurnerCH, DuncanRL, BurrDB, eds. Bridging the Gap Between Dental and Orthopaedic Implants. 3rd Annual Indiana Conference, Indianapolis, IN. 1998.
  • 16
    Huja SS, Fernandez SA, Hill KJ, Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol. 2006; 288: 1243–1249.
  • 17
    Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008; 66: 987–994.
  • 18
    Coleman R, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008; 34: 629–639.
  • 19
    Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001; 7: 478–485.
  • 20
    Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19: 558–567.
  • 21
    Lein M, Wirth M, Miller K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol. 2007; 52: 1381–1387.
  • 22
    Ryan CW, Huo D, Bylow K, et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. Br J Urol Int. 2007; 100: 70–75.
  • 23
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
  • 24
    Bone HG, Hosking D, Devogelaer J-P, et al. gor the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350: 1189–1199.
  • 25
    Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005; 20: 141–151.
    Direct Link:
  • 26
    Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone. 2003; 32: 45–55.
  • 27
    Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006; 24: 4895–4900.
  • 28
    de Lorimier LP, Fan TM. Bone metabolic effects of single-dose zoledronate in healthy dogs. J Vet Intern Med. 2005; 19: 924–927.
  • 29
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077–2082.
  • 30
    Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–1541.
  • 31
    Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006; 39: 872–879.
  • 32
    Foldes J, Shih MS, Parfitt AM. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res. 1990; 5: 1063–1067.
    Direct Link:
  • 33
    Parfitt A, Drezner M, Glorieux F, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987; 2: 595–610.
    Direct Link:
  • 34
    Reinwald S, Burr D. Review of nonprimate, large animal models for osteoporosis research. J Bone Miner Res. 2008; 23: 1353–1368.
    Direct Link:
  • 35
    Burr DB. Targeted and nontargeted remodeling. Bone. 2002; 30: 2–4.
  • 36
    Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354: 2250–2261.
  • 37
    Itoh F, Kojima M, Furihata-Komatsu H, et al. Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res. 2002; 17: 534–543.
    Direct Link:
  • 38
    Yoshida Y, Moriya A, Kitamura K, et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res. 1998; 13: 1011–1022.
    Direct Link:
  • 39
    Mashiba T, Hui S, Turner CH, Mori S, Johnston CC, Burr DB. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int. 2005; 77: 180–185.
  • 40
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000; 15: 613–620.
  • 41
    Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int. 2008; 82: 354–360.
  • 42
    Lafage MH, Balena R, Battle MA, et al. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs: a one-year study. J Clin Invest. 1995; 95: 2127–2133.
  • 43
    Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38: 617–627.
  • 44
    Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone. 2006; 38: 628–636.
  • 45
    Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos. 1992; 20: 473–478.
  • 46
    Usui T, Watanabe T, Higuchi S. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab Dispos. 1995; 23: 1214–1219.
  • 47
    Diab T, Allen MR, Burr DB. Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. Osteoporos Int. 2008; 20: 647–652.
  • 48
    Fan TM, de Lorimier LP, Garrett LD, Lacoste HI. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med. 2008; 22: 380–387.
    Direct Link:
  • 49
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90: 1294–1301.
  • 50
    Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005; 90: 1897–1899.
  • 51
    Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999; 14: 1557–1561.
    Direct Link:
  • 52
    Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001; 91: 144–154.
    Direct Link:
View Full Article (HTML) Get PDF (173K)